Summary

Medicinal chemistry and natural products focus on the discovery, structural characterization, synthesis, modification, and biological evaluation of bioactive molecules. This collection covers synthetic drugs, natural products, pharmacophores, structure–activity relationships, molecular interactions, drug-like properties, and the chemical and biological basis of therapeutic compound development.

Expand All
Entries
Topic Review
Designer Drug Analogues
Designer drug analogues are synthetic or laboratory-prepared structural or functional analogues of substances controlled under national law or international conventions, designed to reproduce the pharmacological effects of a parent drug while circumventing legal control and standard detection [1]. The defining operational logic is deliberate molecular modification: a known psychoactive scaffold is chemically altered—through substitution, chain extension, or ring modification—to generate a compound that retains or exaggerates the biological activity of the parent substance but falls outside existing scheduling provisions [2][3]. Drug analogues are formally classifiable into direct analogues, sharing both chemical and pharmacological similarity with the original; structural analogues, sharing structural features only; and functional analogues, chemically different compounds that display similar pharmacological properties [4]. Contemporary designer drug analogues are organized by chemical scaffold rather than by pharmacological effect, and the principal classes include synthetic cannabinoid receptor agonists, synthetic cathinones, fentanyl and other novel synthetic opioids, phenethylamines, tryptamines, designer benzodiazepines, and dissociative agents [2][5]. Because the analogue is produced by clandestine synthesis rather than pharmaceutical development, its identity and purity are not controlled, and the structural modification that confers legal invisibility may simultaneously increase potency or introduce uncharacterized toxicity [3][5].
  • 17
  • 25 Oct 2026
Topic Review
Computer-Aided Drug Design
Computer-aided drug design (CADD) denotes the integrated application of computational methods, algorithms, and molecular modeling techniques to the identification, formulation, and assessment of pharmaceutical and bioactive substances, operating within a virtual environment that precedes or complements laboratory synthesis and experimental validation [1]. Within the taxonomy of computational drug discovery methods, CADD is defined by its role as a rational, data-driven framework that predicts how a candidate molecule will interact with a disease-related biological target, thereby guiding the selection and optimization of compounds before they are physically produced or tested [2]. The methodological space of CADD is conventionally organized into two complementary families. Structure-based drug design (SBDD) exploits the experimentally resolved or computationally derived three-dimensional structure of a macromolecular target to evaluate the geometric and energetic complementarity of candidate ligands, typically through molecular docking and scoring, and to design or optimize chemical entities that bind with high affinity [3]. Ligand-based drug design (LBDD) proceeds in the absence of a target structure and instead derives predictive models from the known physicochemical and biological properties of a set of active and inactive ligands, using approaches such as quantitative structure–activity relationships (QSAR), pharmacophore modeling, and similarity searching to identify novel candidates with the desired activity profile [2][4]. A defining operational characteristic of CADD is that it enables the exploration of the vast drug-like chemical space at a scale and speed unattainable by experimental high-throughput screening, and it integrates molecular dynamics simulations, virtual screening, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction into a coherent in silico pipeline for hit identification, lead optimization, and drug repurposing [1][3]. The term thus designates the computational toolbox and the rational design logic—spanning target selection, candidate generation, binding assessment, and pharmacokinetic profiling—that collectively constitute the in silico component of modern drug discovery [2][3].
  • 21
  • 25 Oct 2026
Topic Review
Colloidal Drug Delivery Systems
Colloidal drug delivery systems are dispersions of drug-associated particles or supramolecular assemblies within a continuous medium, commonly an aqueous phase [1][2]. Their dispersed components can contain lipids, polymers, or other materials that incorporate a therapeutic substance through encapsulation, partitioning, or association with a surface [2]. Liposomes are one structural class: phospholipid bilayers enclose an aqueous compartment, allowing different drug molecules to occupy the internal fluid or the membrane [1]. Particle composition, size distribution, and surface organization influence colloidal interactions and the disposition of the associated drug [2][3]. Loading methods determine both the amount incorporated and its location within the carrier [3]. Surface modification can change interactions with biological fluids, while carrier destabilization or permeation through its components can release the payload [3][4]. The colloidal particle and the drug therefore have related but distinct transport and clearance behaviours [2][4]. A preparation is characterized by the dispersed structures together with the molecular state and distribution of the drug they contain [1][2][3][4].
  • 7
  • 25 Oct 2026
Topic Review
CNS Drug Delivery
CNS drug delivery is the transport of a therapeutic substance into compartments of the central nervous system, including brain tissue and cerebrospinal fluid [1]. The blood–brain barrier comprises specialized vascular endothelium whose tight junctions, transport systems, and metabolic functions regulate exchange between blood and neural tissue [1][2]. Passive entry varies with molecular properties, while transport proteins can mediate influx or remove compounds from the endothelial membrane and cytoplasm [1]. A drug reaching cerebrospinal fluid does not necessarily distribute uniformly through brain parenchyma, because these compartments have different exchange routes and clearance processes [3]. Nanoparticulate carriers can alter circulation, endothelial interactions, and payload release, but carrier uptake and delivery of active drug are distinct events [2]. Other delivery routes access the nervous system through local administration or specialized anatomical interfaces. The resulting exposure reflects barrier passage, distribution within the target compartment, binding, metabolism, and removal, rather than the concentration measured in blood alone [1][3][4].
  • 9
  • 25 Oct 2026
Topic Review
Buccal Drug Delivery
Buccal drug delivery is the administration of a therapeutic substance to the mucosal lining of the cheek for local action or absorption across the epithelium. A formulation contacts a moist surface exposed to saliva, tissue movement, and clearance into the gastrointestinal tract [1][2]. Drug release and mucosal permeation occur in sequence, while saliva can dilute dissolved material and reduce its residence time. Mucoadhesive polymers prolong contact through interactions with mucus and the underlying mucosal surface [1]. The epithelial barrier regulates passage from the formulation toward the vascularized tissue beneath it, so molecular size and physicochemical characteristics influence absorption [2]. Films, tablets, gels, and devices provide different arrangements for maintaining contact and controlling exposure [1][3]. Device-based approaches can also address the limited passage of therapeutic peptides across the mucosal barrier [3]. For biological macromolecules, preservation of activity and transport across intact tissue remain separate requirements that connect formulation behaviour with the amount reaching the local or systemic compartment [4].
  • 9
  • 25 Oct 2026
Topic Review
Bioisosteric Drug Design
Bioisosteric drug design is the replacement of an atom, functional group, or molecular fragment with another moiety selected to reproduce relevant steric, electronic, or interaction properties in a bioactive molecule. The replacement preserves selected features of molecular recognition while changing properties such as ionization, polarity, conformational preference, or susceptibility to metabolism. Bioisosteric relationships extend beyond atoms of similar valence and include replacements with substantially different chemical connectivity [1]. Saturated carbon frameworks can reproduce the spatial arrangement of substituents on an aromatic ring while changing three-dimensional shape and physicochemical behaviour [2]. For example, appropriately substituted bicyclo[3.1.1]heptanes can approximate the substituent vectors of meta-substituted benzene rings [3]. Functional group replacements can also preserve hydrogen bonding patterns; squaramides offer geometries and donor–acceptor features relevant to several amide-related groups [4]. Equivalence is therefore specific to the molecular setting and the property being preserved, rather than an assertion that two fragments have identical biological effects [1][2].
  • 13
  • 25 Oct 2026
Topic Review
Bioconjugation Techniques
Bioconjugation techniques are methods that covalently connect a biomolecule to another molecular component while retaining the structural features required for its biological activity [1]. Protein and peptide conjugation can target endogenous amino acid side chains or terminal groups, with reaction selectivity governed by functional group reactivity and accessibility [1][2]. Cysteine thiols and lysine amino groups provide common attachment sites, although other residues can also participate in selective transformations [2]. Reactive groups may instead be introduced before conjugation to distinguish the intended site from competing functionalities [1]. Carbonyl groups react with aminooxy or hydrazine derivatives to form oximes or hydrazones, respectively; substrate structure and catalysis affect reaction rates and product stability [3]. Azide-based ligations provide another route to joining components through installed chemical handles [4]. The resulting conjugate may contain one defined attachment site or a distribution of modified sites. Reaction medium, stoichiometry, and chemical compatibility shape both the efficiency of coupling and the molecular composition of the product [1][2][3].
  • 9
  • 28 Oct 2026
Topic Review
Bioconjugated Polymer Therapeutics
Bioconjugated polymer therapeutics constitute a class of macromolecular drug delivery systems in which a therapeutic agent—a low-molecular-weight drug, a peptide, a protein, or a nucleic acid—is covalently linked to a water-soluble polymeric carrier through a chemical linker [1][2]. A typical bioconjugate comprises three basic building blocks: the polymeric carrier molecule, the therapeutic agent, and the chemical linker that joins them; because the therapeutic agent is covalently attached rather than physically encapsulated, the resulting construct functions as a macromolecular prodrug [2][3]. The polymeric carrier is selected for biocompatibility, biodegradability, molecular weight, and the availability of functional groups for conjugation, all of which govern drug loading, release kinetics, and biological performance [2][4]. The linker is a defining structural element: it determines whether the therapeutic agent is released by hydrolysis, by enzymatic cleavage, or by a stimulus-responsive trigger such as pH or redox potential, and it thereby controls the site and kinetics of drug liberation [3][5]. Within advanced drug delivery systems, the term designates these covalently assembled polymer–therapeutic conjugates—including polymer–drug conjugates and polymer–protein conjugates—together with the design logic of carrier selection, linker chemistry, and conjugation strategy that determines their pharmacokinetic profile, targeting capacity, and therapeutic index [2][5][6].
  • 9
  • 25 Oct 2026
Topic Review
Nonribosomal Peptide
Nonribosomal peptides (NRPs) constitute a class of peptide secondary metabolites distinguished by their biosynthetic origin outside the ribosomal machinery, being assembled by dedicated multimodular enzyme systems rather than translated from a messenger RNA template. This nonribosomal origin confers upon NRPs a defining structural freedom: their monomeric building blocks are not restricted to the 21 proteinogenic amino acids but extend to a vast repertoire of nonproteinogenic residues, including D-amino acids, hydroxy acids, aryl acids, and other non-canonical units [1][2]. The structural consequences of this freedom are substantial. NRPs frequently adopt cyclic or branched architectures, contain non-standard peptide bonds and modified side chains, and exhibit a degree of structural complexity—encompassing macrocyclic rings, heterocyclic elements, and diverse tailoring modifications—that far exceeds the range accessible to ribosomal peptides [2][3]. The term encompasses a pharmacologically significant array of compounds, including glycopeptide antibiotics such as vancomycin, lipopeptides such as daptomycin, immunosuppressants such as cyclosporine, antitumor agents such as bleomycin, and siderophores such as enterobactin [4][5]. Within the taxonomy of microbial natural products and biosynthesis, NRPs are defined as ribosome-independent peptide natural products whose structural diversity and biological activity derive from the incorporation of nonproteinogenic building blocks and from extensive post-assembly modification, rather than from direct gene-encoded translation [1][2].
  • 18
  • 25 Oct 2026
Topic Review
Isoprenoid
An isoprenoid is a compound whose carbon framework has a biosynthetic origin in the five-carbon precursors isopentenyl diphosphate and dimethylallyl diphosphate. The family includes sterols, prenyl groups, and numerous other compounds assembled from these activated building blocks. The mevalonate pathway supplies precursors for several branches of isoprenoid metabolism [1]. Farnesyl and geranylgeranyl groups are isoprenoid units that can be covalently attached to proteins through prenylation reactions [2]. In plants, precursor production occurs through both the cytosolic mevalonate pathway and the plastidial methylerythritol phosphate pathway [3]. Chain extension, cyclization, and subsequent chemical modifications generate products with distinct molecular structures and functional groups [4]. Their common precursor origin connects this chemical diversity within a single biosynthetic family despite substantial variation in molecular size and final structure [5].
  • 5
  • 25 Oct 2026
  • Page
  • of
  • 5

Other Entry Collections

>>